One should note that >20% of the present patients were taking OAC at baseline, mainly because most patients were enrolled before the publication of the results from NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) and RE‐SPECT ESUS that did not show the superiority of direct OACs to aspirin for secondary prevention of ESUS.39, 42. Here, F10 is linked to stroke disorder.